Standard BioTools (FLB) AI Stock Analysis

4 Followers

Standard BioTools

(Frankfurt:FLB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageVery low leverage and positive equity provide financial flexibility while the company restructures its portfolio. This reduces balance-sheet pressure relative to many loss-making businesses and preserves capacity to fund operations or strategic priorities as performance improves.

Negative Factors

Revenue contractionPersistent revenue contraction and volatility make it harder to absorb fixed costs, plan investment, and achieve operating leverage. Unless demand recovers, weaker scale can keep profitability under pressure and limit the company’s ability to convert its platform portfolio into durable growth.

Standard BioTools (FLB) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 243.14M
Dividend Yield: ―
Average Volume (3M): 800
Price to Earnings (P/E): -5.6
Beta (1Y): 0.71
Revenue Growth: -38.68%
EPS Growth: 50.33%
Country: Germany
Employees: 387
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East,...

Standard BioTools Earnings Call Summary

Earnings Call Date:May 05, 2025(Q1-2025)|% Change Since:-45.96%|Next Earnings Date:―

Earnings Call SentimentNeutral

The earnings call reflected a well-managed quarter with robust strategic initiatives and strong cost management, despite facing significant revenue declines and challenges in the U.S. academic market. The company's strong cash position and strategic product expansions provide a positive outlook, though the impact of tariffs and revenue declines remain concerns.

Positive Updates

Strategic Product Launches and Expansions

Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.

Negative Updates

Revenue Decline

Total revenue fell by 10% year-over-year, with consumables down by 16% and services down by 16%, due to lower volumes and project timing.

Company Guidance

During the Standard BioTools first quarter 2025 earnings call, the company reiterated its full-year revenue guidance of $165 million to $175 million, despite a 10% year-over-year decline in Q1 revenue to $40.8 million. The decline was primarily due to lower consumables and services revenue, with consumables down 16% and services down 16% year-over-year. Instrument sales, however, grew by 24%, driven by the Hyperion XTi system. The company reported non-GAAP gross margins of 53.2%, impacted by lower volumes and product mix, and a non-GAAP operating loss improvement of 45% year-over-year. Adjusted EBITDA loss improved 29% to $16.9 million, and cash burn was reduced by 33%. The company emphasized its strategic focus on proteomics and highlighted new product launches, including the CyTOF-XT Pro and SomaScan Select Asset, as key drivers for future growth.

Standard BioTools Risk Analysis

Standard BioTools disclosed 50 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.We could fail to maintain the listing of our common stock on the Nasdaq Stock Market LLC ("Nasdaq"), which could seriously harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction.Q1, 2026

Standard BioTools Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:FLB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MLAB	66Neutral	$702.17M	146.73	2.59%	0.51%	3.04%	―
MASS	60Neutral	$441.03M	-11.90	-25.50%	―	0.72%	56.39%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDAI	46Neutral	$48.28M	-4.39	120.69%	―	-44.99%	48.57%
QDEL	45Neutral	$966.23M	-2.64	-20.13%	―	-4.62%	68.20%
TRIB	41Neutral	$4.23M	-0.14	48.72%	―	-13.28%	39.65%

* Healthcare Sector Average

Performance Comparison

DE:FLB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:FLB	Standard Biotools Inc	0.54	-0.43	-44.56%
MLAB	Mesa Laboratories	126.19	51.80	69.64%
QDEL	Quidelortho Corporation	14.35	-6.91	-32.50%
TRIB	Trinity Biotech	6.43	-22.26	-77.60%
MASS	908 Devices Inc.	11.07	3.27	41.92%
MDAI	Spectral Ai, Inc. Class A	1.53	-0.41	-21.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Standard BioTools AI Stock Analysis